These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 9102202)

  • 1. Distinct somatic genetic changes associated with tumor progression in carriers of BRCA1 and BRCA2 germ-line mutations.
    Tirkkonen M; Johannsson O; Agnarsson BA; Olsson H; Ingvarsson S; Karhu R; Tanner M; Isola J; Barkardottir RB; Borg A; Kallioniemi OP
    Cancer Res; 1997 Apr; 57(7):1222-7. PubMed ID: 9102202
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BRCA1 and BRCA2 mutation status and tumor characteristics in male breast cancer: a population-based study in Italy.
    Ottini L; Masala G; D'Amico C; Mancini B; Saieva C; Aceto G; Gestri D; Vezzosi V; Falchetti M; De Marco M; Paglierani M; Cama A; Bianchi S; Mariani-Costantini R; Palli D
    Cancer Res; 2003 Jan; 63(2):342-7. PubMed ID: 12543786
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High incidence of loss of heterozygosity in breast tumors from carriers of the BRCA2 999del5 mutation.
    Ingvarsson S; Geirsdottir EK; Johannesdottir G; Sigbjörnsdóttir BI; Eiriksdottir G; Ragnarsson G; Agnarsson BA; Gudmundsson J; Jonasson JG; Sigurdsson A; Egilsson V; Barkardottir RB
    Cancer Res; 1998 Oct; 58(19):4421-5. PubMed ID: 9766673
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutations of the BRCA1 and BRCA2 genes in patients with bilateral breast cancer.
    Steinmann D; Bremer M; Rades D; Skawran B; Siebrands C; Karstens JH; Dörk T
    Br J Cancer; 2001 Sep; 85(6):850-8. PubMed ID: 11556836
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The frequency of germ-line mutations in the breast cancer predisposition genes BRCA1 and BRCA2 in familial prostate cancer. The Cancer Research Campaign/British Prostate Group United Kingdom Familial Prostate Cancer Study Collaborators.
    Gayther SA; de Foy KA; Harrington P; Pharoah P; Dunsmuir WD; Edwards SM; Gillett C; Ardern-Jones A; Dearnaley DP; Easton DF; Ford D; Shearer RJ; Kirby RS; Dowe AL; Kelly J; Stratton MR; Ponder BA; Barnes D; Eeles RA
    Cancer Res; 2000 Aug; 60(16):4513-8. PubMed ID: 10969800
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Distinct genomic profiles in hereditary breast tumors identified by array-based comparative genomic hybridization.
    Jönsson G; Naylor TL; Vallon-Christersson J; Staaf J; Huang J; Ward MR; Greshock JD; Luts L; Olsson H; Rahman N; Stratton M; Ringnér M; Borg A; Weber BL
    Cancer Res; 2005 Sep; 65(17):7612-21. PubMed ID: 16140926
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A high occurrence of BRCA1 and BRCA2 mutations among Czech hereditary breast and breast-ovarian cancer families.
    Machácková E; Foretová L; Navrátilová M; Valík D; Claes K; Messiaen L
    Cas Lek Cesk; 2000 Oct; 139(20):635-7. PubMed ID: 11192759
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CAG and GGC repeat polymorphisms in the androgen receptor gene and breast cancer susceptibility in BRCA1/2 carriers and non-carriers.
    Kadouri L; Easton DF; Edwards S; Hubert A; Kote-Jarai Z; Glaser B; Durocher F; Abeliovich D; Peretz T; Eeles RA
    Br J Cancer; 2001 Jul; 85(1):36-40. PubMed ID: 11437399
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Double heterozygosity for mutations in the BRCA1 and BRCA2 genes in a breast cancer patient.
    Tsongalis GJ; Linfert DR; Johnson RC; Ackroyd R; Berman MM; Ricci A
    Arch Pathol Lab Med; 1998 Jun; 122(6):548-50. PubMed ID: 9625424
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative genomic hybridization profiles in human BRCA1 and BRCA2 breast tumors highlight differential sets of genomic aberrations.
    van Beers EH; van Welsem T; Wessels LF; Li Y; Oldenburg RA; Devilee P; Cornelisse CJ; Verhoef S; Hogervorst FB; van't Veer LJ; Nederlof PM
    Cancer Res; 2005 Feb; 65(3):822-7. PubMed ID: 15705879
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histology of prophylactically removed ovaries from BRCA1 and BRCA2 mutation carriers compared with noncarriers in hereditary breast ovarian cancer syndrome kindreds.
    Casey MJ; Bewtra C; Hoehne LL; Tatpati AD; Lynch HT; Watson P
    Gynecol Oncol; 2000 Sep; 78(3 Pt 1):278-87. PubMed ID: 10985881
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population-based estimate of the average age-specific cumulative risk of breast cancer for a defined set of protein-truncating mutations in BRCA1 and BRCA2. Australian Breast Cancer Family Study.
    Hopper JL; Southey MC; Dite GS; Jolley DJ; Giles GG; McCredie MR; Easton DF; Venter DJ
    Cancer Epidemiol Biomarkers Prev; 1999 Sep; 8(9):741-7. PubMed ID: 10498392
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A predictor based on the somatic genomic changes of the BRCA1/BRCA2 breast cancer tumors identifies the non-BRCA1/BRCA2 tumors with BRCA1 promoter hypermethylation.
    Alvarez S; Diaz-Uriarte R; Osorio A; Barroso A; Melchor L; Paz MF; Honrado E; Rodríguez R; Urioste M; Valle L; Díez O; Cigudosa JC; Dopazo J; Esteller M; Benitez J
    Clin Cancer Res; 2005 Feb; 11(3):1146-53. PubMed ID: 15709182
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular classification of breast carcinomas by comparative genomic hybridization: a specific somatic genetic profile for BRCA1 tumors.
    Wessels LF; van Welsem T; Hart AA; van't Veer LJ; Reinders MJ; Nederlof PM
    Cancer Res; 2002 Dec; 62(23):7110-7. PubMed ID: 12460933
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunohistochemical characteristics defined by tissue microarray of hereditary breast cancer not attributable to BRCA1 or BRCA2 mutations: differences from breast carcinomas arising in BRCA1 and BRCA2 mutation carriers.
    Palacios J; Honrado E; Osorio A; Cazorla A; Sarrió D; Barroso A; Rodríguez S; Cigudosa JC; Diez O; Alonso C; Lerma E; Sánchez L; Rivas C; Benítez J
    Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3606-14. PubMed ID: 14506147
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Distinct molecular pathogeneses of early-onset breast cancers in BRCA1 and BRCA2 mutation carriers: a population-based study.
    Armes JE; Trute L; White D; Southey MC; Hammet F; Tesoriero A; Hutchins AM; Dite GS; McCredie MR; Giles GG; Hopper JL; Venter DJ
    Cancer Res; 1999 Apr; 59(8):2011-7. PubMed ID: 10213514
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Allelic loss at BRCA1, BRCA2, and adjacent loci in relation to TP53 abnormality in breast cancer.
    Tseng SL; Yu IC; Yue CT; Chang SF; Chang TM; Wu CW; Shen CY
    Genes Chromosomes Cancer; 1997 Dec; 20(4):377-82. PubMed ID: 9408754
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Frequent somatic loss of BRCA1 in breast tumours from BRCA2 germ-line mutation carriers and vice versa.
    Staff S; Isola JJ; Johannsson O; Borg A; Tanner MM
    Br J Cancer; 2001 Oct; 85(8):1201-5. PubMed ID: 11710835
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.
    Casey MJ; Synder C; Bewtra C; Narod SA; Watson P; Lynch HT
    Gynecol Oncol; 2005 May; 97(2):457-67. PubMed ID: 15863145
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel somatic mutations in the BRCA1 gene in sporadic breast tumors.
    Janatova M; Zikan M; Dundr P; Matous B; Pohlreich P
    Hum Mutat; 2005 Mar; 25(3):319. PubMed ID: 15712267
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.